Alzheimer's disease (AD) is a neurodegenerative disease with a long preclinical and prodromal stage near 20 years. The neuropathological hallmarks of AD include amyloid plaques, neurofibrillary tangles, and neuroinflammation, those lead to neuronal and synaptic loss. Important fact, oxidative stress participates in the AD development by promoting amyloid-β deposition, tau hyperphosphorylation. However, the inflammatory response and pyroptotic death are mediated by the aberrant expression of NLRP inflammasome activated caspase-1, which leads to cleavage pro-inflammatory cytokines such as pro-interleukin-1β and pro-IL-18. IL-1β, TNF-α, and IL-6 which amplify the neuroinflammation loop, are produce by activated microglia and astrocytes, that can serve as early diagnostic markers or therapeutic targets in AD. In this review, we summarize our current understanding of the role of inflammasome in the pathogenesis of AD, highlighting key issues that need to be addressed to improve the development of new therapies.
LiXFengXSunX, et al.Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2019. Front Aging Neurosci2022; 14: 937486.
2.
KumarASidhuJGoyalA, et al.Alzheimer disease. Treasure Island (FL): StatPearls, 2024.
3.
HippiusHNeundörferG. The discovery of Alzheimer’s disease. Dialogues Clin Neurosci2003; 5: 101–108.
4.
GlennerGGWongCWQuarantaV, et al.The amyloid deposits in Alzheimer’s disease: their nature and pathogenesis. Appl Pathol1984; 2: 357–369.
5.
IttnerLMGötzJ. Amyloid-β and tau–a toxic pas de deux in Alzheimer’s disease. Nat Rev Neurosci2011; 12: 65–72.
6.
GoedertMEisenbergDSCrowtherRA. Propagation of tau aggregates and neurodegeneration. Annu Rev Neurosci2017; 40: 189–210.
7.
CicconeLShiCdi LorenzoD, et al.The positive side of the Alzheimer’s disease amyloid cross-interactions: The case of the Aβ 1-42 peptide with Tau, TTR, CysC, and ApoA1. Molecules2020; 25: 2439.
8.
HardyJSelkoeDJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science2002; 297: 353–356.
9.
BrierMRGordonBFriedrichsenK, et al.Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease. Sci Transl Med2016; 8: 338ra66.
10.
DeTureMADicksonDW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener2019; 14: 32.
11.
SahaPSenN. Tauopathy: A common mechanism for neurodegeneration and brain aging. Mech Ageing Dev2019; 178: 72–79.
12.
RabinoviciGDGatsonisCApgarC, et al.Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA2019; 321: 1286–1294.
13.
UddinMKabirMJalouliM, et al.Neuroinflammatory signaling in the pathogenesis of Alzheimer’s disease. Curr Neuropharmacol2022; 20: 126–146.
14.
ZhangWXiaoDMaoQ, et al.Role of neuroinflammation in neurodegeneration development. Sig Transduct Target Ther2023; 8: 267.
15.
Solleiro-VillavicencioHRivas-ArancibiaS. Effect of chronic oxidative stress on neuroinflammatory response mediated by CD4+T cells in neurodegenerative diseases. Front Cell Neurosci2018; 12: 114.
16.
HuangXHussainBChangJ. Peripheral inflammation and blood–brain barrier disruption: effects and mechanisms. CNS Neurosci Ther2020; 27: 36–47.
17.
SarlusHHenekaMT. Microglia in Alzheimer’s disease. J Clin Invest127: 3240–3249.
18.
ShiYHoltzmanDM. Interplay between innate immunity and Alzheimer’s disease: APOE and TREM2 in the spotlight. Nat Rev Immunol2018; 18: 759–772.
19.
CaiYLiuJWangB, et al.Microglia in the neuroinflammatory pathogenesis of Alzheimer’s disease and related therapeutic targets. Front Immunol2022; 13: 856376.
20.
MiaoJMaHYangY, et al.Microglia in Alzheimer’s disease: pathogenesis, mechanisms, and therapeutic potentials. Front Aging Neurosci2023; 15: 1201982.
21.
Meraz RiosMAToral-RiosDFranco-BocanegraD, et al.Inflammatory process in Alzheimer’s disease. Front Integr Neurosci2013; 7: 00059.
22.
JinYSongYLinJ, et al.Role of inflammation in neurological damage and regeneration following spinal cord injury and its therapeutic implications. Burns Trauma2023; 11: tkac054.
23.
CalsolaroVEdisonP. Neuroinflammation in Alzheimer’s disease: Current evidence and future directions. Alzheimers Dement2016; 12: 719–732.
24.
CombsCKKarloJCKaoS-C, et al.β-Amyloid stimulation of microglia and monocytes results in TNFα-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci2001; 21: 1179–1188.
25.
YamamotoMKiyotaTHoribaM, et al.Interferon-γ and tumor necrosis factor-α regulate amyloid-β plaque deposition and β-secretase expression in swedish mutant APP transgenic mice. Am J Pathol2007; 170: 680–692.
26.
DominguesCCruz e SilvaOABHenriquesAG. Impact of cytokines and chemokines on Alzheimer’s Disease neuro-pathological hallmarks. Curr Alzheimer Res2017; 14: 870–882.
27.
AlbornozEAWoodruffTMGordonR. Inflammasomes in CNS diseases. Exp Suppl2018; 108: 41–60.
28.
SwansonKVDengMTingJP-Y. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol2019; 19: 477–489.
29.
LiangTZhangYWuS, et al.The Role of NLRP3 inflammasome in Alzheimer’s disease and potential therapeutic targets. Front Pharmacol2022; 13: 845185.
30.
HanCYangYGuanQ, et al.New mechanism of nerve injury in Alzheimer’s disease: β-amyloid-induced neuronal pyroptosis. J Cell Mol Med2020; 24: 8078–8090.
31.
NelsonPTAlafuzoffIBigioEH, et al.Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol2012; 71: 362–381.
32.
SpielmeyerW. Ziele und wege der histopathologie des nervensystems. In: SpielmeyerW (ed.) Histopathologie des Nervensystems: Erster Band Allgemeiner Teil. Berlin, Heidelberg: Springer, 1–11.
33.
BraakHBraakE. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging1997; 18: 351–357.
34.
WalkerJMGoetteWFarrellK, et al.The relationship between hippocampal amyloid beta burden and spatial distribution of neurofibrillary degeneration. Alzheimers Dement2023; 19: 3158–3170.
35.
HymanBTVan HoesenGWDamasioAR, et al.Alzheimer’s disease: cell-specific pathology isolates the hippocampal formation. Science1984; 225: 1168–1170.
36.
HymanBTVan HoesenGWKromerLJ, et al.Perforant pathway changes and the memory impairment of Alzheimer’s disease. Ann Neurol1986; 20: 472–481.
37.
EdwardsFA. A unifying hypothesis for Alzheimer’s disease: from plaques to neurodegeneration. Trends Neurosci2019; 42: 310–322.
38.
PereiraJBJanelidzeSOssenkoppeleR, et al.Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease. Brain2021; 144: 310–324.
39.
HampelHHardyJBlennowK. The amyloid-β pathway in Alzheimer’s disease. Mol Psychiatry2021; 26: 5481–5503.
40.
MatarinMSalihDAYasvoinaM, et al.A Genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology. Cell Reports2015; 10: 633–644.
41.
in t’ VeldBARuitenbergAHofmanA, et al.Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med2001; 345: 1515–1521.
42.
McGeerPLMcGeerERogersJ, et al.Anti-inflammatory drugs and Alzheimer disease. Lancet1990; 335: 1037.
43.
RichJBRasmussonDXFolsteinMF, et al.Nonsteroidal anti-inflammatory drugs in Alzheimer’s disease. Neurology1995; 45: 51–55.
44.
StewartWFKawasCCorradaM, et al.Risk of Alzheimer’s disease and duration of NSAID use. Neurology1997; 48: 626–632.
45.
BennettDASchneiderJAWilsonRS, et al.Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol2004; 61: 378–384.
46.
HampelHCaraciFCuelloAC, et al.A path toward precision medicine for neuroinflammatory mechanisms in Alzheimer’s disease. Front Immunol2020; 11: 456.
47.
HenekaMTCarsonMJEl KhouryJ, et al.Neuroinflammation in Alzheimer’s disease. Lancet Neurol2015; 14: 388–405.
48.
RogersJWebsterSLueLF, et al.Inflammation and Alzheimer’s disease pathogenesis. Neurobiol Aging1996; 17: 681–686.
49.
EikelenboomPZhanSSvan GoolWA, et al.Inflammatory mechanisms in Alzheimer’s disease. Trends Pharmacol Sci1994; 15: 447–450.
50.
IulitaMFGaneshAPentzR, et al.Identification and preliminary validation of a plasma profile associated with cognitive decline in dementia and at-risk individuals: a retrospective cohort analysis. J Alzheimers Dis2019; 67: 327–341.
51.
RogersJ. Principles for central nervous system inflammation research: A call for a consortium approach. Alzheimers Dement2018; 14: 1553–1559.
52.
BrosseronFKrauthausenMKummerM, et al.Body fluid cytokine levels in mild cognitive impairment and Alzheimer’s disease: a comparative overview. Mol Neurobiol2014; 50: 534–544.
53.
NordengenKKirsebomB-EHenjumK, et al.Glial activation and inflammation along the Alzheimer’s disease continuum. J Neuroinflammation2019; 16: 46.
54.
ParboPIsmailRHansenKV, et al.Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer’s disease. Brain2017; 140: 2002–2011.
55.
NordenDMTrojanowskiPJVillanuevaE, et al.Sequential activation of microglia and astrocyte cytokine expression precedes increased Iba-1 or GFAP immunoreactivity following systemic immune challenge. Glia2016; 64: 300–316.
56.
WangSColonnaM. Microglia in Alzheimer’s disease: A target for immunotherapy. J Leukoc Biol2019; 106.
57.
StreitWJXueQ-STischerJ, et al.Microglial pathology. Acta Neuropathol Commun2014; 2: 142.
58.
WangYZhuTWangM, et al.Icariin attenuates M1 activation of microglia and Aβ plaque accumulation in the hippocampus and prefrontal cortex by up-regulating PPARγ in restraint/isolation-stressed APP/PS1 mice. Front Neurosci2019; 13: 291.
59.
MyersJS. Proinflammatory cytokines and sickness behavior: Implications for depression and cancer-related symptoms. Oncol Nurs Forum2008; 35: 802–807.
60.
DantzerRO’ConnorJCFreundGG, et al.From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci2008; 9: 46–56.
61.
CarsonMJDooseJMMelchiorB, et al.CNS immune privilege: hiding in plain sight. Immunol Rev2006; 213: 48–65.
62.
PuntambekarSSDavisDSHawelL, et al.LPS-induced CCL2 expression and macrophage influx into the murine central nervous system is polyamine-dependent. Brain Behav Immun2011; 25: 629–639.
63.
WohlebESPowellNDGodboutJP, et al.Stress-induced recruitment of bone marrow-derived monocytes to the brain promotes anxiety-like behavior. J Neurosci2013; 33: 13820–13833.
64.
JaturapatpornDIsaacMMcCleeryJ, et al.Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer’s disease. Cochrane Database Syst Rev2012: CD006378.
65.
TerryRDMasliahESalmonDP, et al.Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol1991; 30: 572–580.
66.
EscartinCGaleaELakatosA, et al.Reactive astrocyte nomenclature, definitions, and future directions. Nat Neurosci2021; 24: 312–325.
67.
HenekaMTGolenbockDTLatzE. Innate immunity in Alzheimer’s disease. Nat Immunol2015; 16: 229–236.
68.
LučiūnaitėAMcManusRJankunecM, et al.Soluble Aβ oligomers and protofibrils induce NLRP3 inflammasome activation in microglia. J Neurochem2023; 155: 650–661.
69.
ChoiS-BKwonSKimJ-H, et al.The molecular mechanisms of neuroinflammation in Alzheimer’s disease, the consequence of neural cell death. Int J Mol Sci2023; 24: 11757.
70.
StamouliECPolitisAM. Pro-inflammatory cytokines in Alzheimer’s disease. Psychiatriki2016; 27: 264–275.
71.
RajeshYKannegantiT-D. Innate immune cell death in neuroinflammation and Alzheimer’s disease. Cells2022; 11: 1885.
72.
WojcieszakJKuczyńskaKZawilskaJB. Role of chemokines in the development and progression of Alzheimer’s disease. J Mol Neurosci2022; 72: 1929–1951.
73.
MawuenyegaKGSigurdsonWOvodV, et al.Decreased clearance of CNS amyloid-β in Alzheimer’s disease. Science2010; 330: 1774.
74.
SierksmaALuAMancusoR, et al.Novel Alzheimer risk genes determine the microglia response to amyloid-β but not to tau pathology. EMBO Mol Med2020; 12: e10606.
BambergerMEHarrisMEMcDonaldDR, et al.A cell surface receptor complex for fibrillar β-amyloid mediates microglial activation. J Neurosci2003; 23: 2665–2674.
77.
LiuYWalterSStagiM, et al.LPS receptor (CD14): a receptor for phagocytosis of Alzheimer’s amyloid peptide. Brain2005; 128: 1778–1789.
78.
ZakariaRWan YaacobWMOthmanZ, et al.Lipopolysaccharide-induced memory impairment in rats: a model of Alzheimer’s disease. Physiol Res2017; 66: 553–565.
79.
ZhanXStamovaBJinL-W, et al.Gram-negative bacterial molecules associate with Alzheimer disease pathology. Neurology2016; 87: 2324–2332.
80.
ZhaoYJaberVLukiwWJ. Secretory products of the human GI tract microbiome and their potential impact on Alzheimer’s disease (AD): Detection of lipopolysaccharide (LPS) in AD hippocampus. Front Cell Infect Microbiol2017; 7: 318.
81.
HerrupK. The case for rejecting the amyloid cascade hypothesis. Nat Neurosci2015; 18: 794–799.
82.
MusiekESHoltzmanDM. Three dimensions of the amyloid hypothesis: Time, space, and “wingmen”. Nat Neurosci2015; 18: 800–806.
83.
ChidambaramHDasRChinnathambiS. Interaction of tau with the chemokine receptor, CX3CR1 and its effect on microglial activation, migration and proliferation. Cell Biosci2020; 10: 109.
84.
d’ErricoPZiegler-WaldkirchSAiresV, et al.Microglia contribute to the propagation of Aβ into unaffected brain tissue. Nat Neurosci2022; 25: 20–25.
85.
BolósMLlorens-MartínMPereaJR, et al.Absence of CX3CR1 impairs the internalization of Tau by microglia. Mol Neurodegener2017; 12: 59.
86.
PawelecPZiemka-NaleczMSypeckaJ, et al.The impact of the CX3CL1/CX3CR1 axis in neurological disorders. Cells2020; 9: 2277.
87.
BolósMPereaJRTerreros-RoncalJ, et al.Absence of microglial CX3CR1 impairs the synaptic integration of adult-born hippocampal granule neurons. Brain Behav Immun2018; 68: 76–89.
88.
TakedaSWegmannSChoH, et al.Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer’s disease brain. Nat Commun2015; 6: 8490.
89.
McInnesJWierdaKSnellinxA, et al.Synaptogyrin-3 mediates presynaptic dysfunction induced by tau. Neuron2018; 97: 823–835.e8.
90.
CalafateSFlavinWVerstrekenP, et al.Loss of bin1 promotes the propagation of tau pathology. Cell Rep2016; 17: 931–940.
91.
CohenJTorresC. Astrocyte senescence: Evidence and significance. Aging Cell2019; 18: e12937.
92.
ArranzAMDe StrooperB. The role of astroglia in Alzheimer’s disease: pathophysiology and clinical implications. Lancet Neurol2019; 18: 406–414.
93.
HarryGJ. Microglia during development and aging. Pharmacol Ther2013; 139: 313–326.
94.
GrahamLCNaldrettMJKohamaSG, et al.Regional molecular mapping of primate synapses during normal healthy aging. Cell Rep2019; 27: 1018–1026.e4.
95.
Vom BergJProkopSMillerKR, et al.Inhibition of IL-12/IL-23 signaling reduces Alzheimer’s disease-like pathology and cognitive decline. Nat Med2012; 18: 1812–1819.
96.
GuerreiroRJSantanaIBrásJM, et al.Peripheral inflammatory cytokines as biomarkers in Alzheimer’s disease and mild cognitive impairment. Neurodegener Dis2007; 4: 406–412.
97.
GriffinWST. Neuroinflammatory cytokine signaling and Alzheimer’s disease. N Engl J Med2013; 368: 770–771.
98.
BelkhelfaMBekrarSRezaigL, et al.Neuroinflammatory responses occur in brain lesions during Alzheimer’s disease: postmortem case report. J Alzheimers Dis2024; 97: 1323–1339.
99.
LueLFWalkerDGRogersJ. Modeling microglial activation in Alzheimer’s disease with human postmortem microglial cultures. Neurobiol Aging2001; 22: 945–956.
100.
ShenX-NNiuL-DWangY-J, et al.Inflammatory markers in Alzheimer’s disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies. J Neurol Neurosurg Psychiatry2019; 90: 590–598.
101.
SwardfagerWLanctôtKRothenburgL, et al.A meta-analysis of cytokines in Alzheimer’s disease. Biol Psychiatry2010; 68: 930–941.
102.
MrakREGriffinWS. Interleukin-1, neuroinflammation, and Alzheimer’s disease. Neurobiol Aging2001; 22: 903–908.
103.
TarkowskiELiljerothAMMinthonL, et al.Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. Brain Res Bull2003; 61: 255–260.
104.
TeixeiraALReisHJCoelhoFM, et al.All-or-nothing type biphasic cytokine production of human lymphocytes after exposure to Alzheimer’s beta-amyloid peptide. Biol Psychiatry2008; 64: 891–895.
105.
HesseRWahlerAGummertP, et al.Decreased IL-8 levels in CSF and serum of AD patients and negative correlation of MMSE and IL-1β. BMC Neurol2016; 16: 185.
106.
SunY-XMinthonLWallmarkA, et al.Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer’s disease. Dement Geriatr Cogn Disord2003; 16: 136–144.
107.
LeungRProitsiPSimmonsA, et al.Inflammatory proteins in plasma are associated with severity of Alzheimer’s disease. PLoS One2013; 8: e64971.
108.
McAlpineFETanseyMG. Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer’s disease. J Inflamm Res2008; 1: 29–39.
109.
EkertJOGouldRLReynoldsG, et al.TNF alpha inhibitors in Alzheimer’s disease: A systematic review. Int J Geriatr Psychiatry2018; 33: 688–694.
110.
IulitaMFCaraciFCuelloAC. A link between nerve growth factor metabolic deregulation and amyloid-β-driven inflammation in Down syndrome. CNS Neurol Disord Drug Targets2023; 15: 434–447.
LedoJHAzevedoEPBeckmanD, et al.Cross talk between brain innate immunity and serotonin signaling underlies depressive-like behavior induced by Alzheimer’s amyloid-β oligomers in mice. J Neurosci2016; 36: 12106–12116.
113.
CaraciFSpampinatoSFMorgeseMG, et al.Neurobiological links between depression and AD: The role of TGF-β1 signaling as a new pharmacological target. Pharmacol Res2018; 130: 374–384.
114.
LiaoY-FWangB-JChengH-T, et al.Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J Biol Chem2004; 279: 49523–49532.
115.
Koenigsknecht-TalbooJLandrethGE. Microglial phagocytosis induced by fibrillar β-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci2005; 25: 8240–8249.
116.
ClarkIAtwoodCBowenR, et al.Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer’s disease links numerous treatment rationales. Pharmacol Rev2012; 64: 1004–1026.
117.
LourencoMVClarkeJRFrozzaRL, et al.TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer’s β-amyloid oligomers in mice and monkeys. Cell Metab2013; 18: 831–843.
118.
BelkhelfaMRafaHMedjeberO, et al.IFN-γ and TNF-α are involved during Alzheimer disease progression and correlate with nitric oxide production: a study in Algerian patients. J Interferon Cytokine Res2014; 34: 839–847.
119.
SuganthyNAlyHFGunnarssonL-G, et al.Alzheimer’s Disease & Treatment, Vol. 1. Open Access eBooks, 2018, pp.1–125.
120.
ShamimDLaskowskiM. Inhibition of inflammation mediated through the tumor necrosis factor α biochemical pathway can lead to favorable outcomes in Alzheimer disease. J Cent Nerv Syst Dis2017; 9: 1179573517722512.
121.
LueLFRydelRBrighamEF, et al.Inflammatory repertoire of Alzheimer’s disease and nondemented elderly microglia in vitro. Glia2001; 35: 72–79.
122.
LaskeCStranskyEHoffmannN, et al.Macrophage colony-stimulating factor (M-CSF) in plasma and CSF of patients with mild cognitive impairment and Alzheimer’s disease. Curr Alzheimer Res2010; 7: 409–414.
123.
Hirsch-ReinshagenVMaiaLFBurgessBL, et al.The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J Biol Chem2005; 280: 43243–43256.
124.
HenekaMTKummerMPStutzA, et al.NLRP3 is activated in Alzheimeŕs disease and contributes to pathology in APP/PS1 mice. Nature2013; 493: 674–678.
125.
AkamaKTVan EldikLJ. Beta-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1beta- and tumor necrosis factor-alpha (TNFalpha)-dependent, and involves a TNFalpha receptor-associated factor- and NFkappaB-inducing kinase-dependent signaling mechanism. J Biol Chem2000; 275: 7918–7924.
126.
GaoCJiangJTanY, et al.Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. Signal Transduct Target Ther2023; 8: 359.
127.
MrakREShengJGGriffinWST. Glial cytokines in Alzheimer’s disease. Hum Pathol1995; 26: 816–823.
128.
TarkowskiEAndreasenNTarkowskiA, et al.Intrathecal inflammation precedes development of Alzheimer’s disease. J Neurol Neurosurg Psychiatry2003; 74: 1200–1205.
129.
ZelcerNKhanlouNClareR, et al.Attenuation of neuroinflammation and Alzheimer’s disease pathology by liver x receptors. Proc Natl Acad Sci U S A2007; 104: 10601–10606.
130.
UeberhamUUeberhamEGruschkaH, et al.Altered subcellular location of phosphorylated Smads in Alzheimer’s disease. Eur J Neurosci2006; 24: 2327–2334.
131.
TesseurIZouKEspositoL, et al.Deficiency in neuronal TGF-β signaling promotes neurodegeneration and Alzheimer’s pathology. J Clin Invest2006; 116: 3060–3069.
132.
SongLGuYJieJ, et al.Dab2 attenuates brain injury in APP/PS1 mice via targeting transforming growth factor-beta/SMAD signaling. Neural Regen Res2014; 9: 41–50.
133.
TorrisiSAGeraciFTropeaMR, et al.Fluoxetine and vortioxetine reverse depressive-like phenotype and memory deficits induced by Aβ1-42 oligomers in mice: A key role of transforming growth factor-β1. Front Pharmacol2019; 10: 693.
134.
ChenJKeKLuJ, et al.Protection of TGF-β1 against neuroinflammation and neurodegeneration in Aβ1–42-induced Alzheimer’s disease model rats. PLoS One2015; 10: e0116549.
135.
CaraciFSpampinatoSSortinoMA, et al.Dysfunction of TGF-β1 signaling in Alzheimer’s disease: perspectives for neuroprotection. Cell Tissue Res2012; 347: 291–301.
136.
TichauerJEvon BernhardiR. Transforming growth factor-β stimulates β amyloid uptake by microglia through Smad3-dependent mechanisms. J Neurosci Res2012; 90: 1970–1980.
137.
CaraciFGulisanoWGuidaCA, et al.A key role for TGF-β1 in hippocampal synaptic plasticity and memory. Sci Rep2015; 5: 11252.
138.
HerrupK. The involvement of cell cycle events in the pathogenesis of Alzheimer’s disease. Alzheimers Res Ther2010; 2: 13.
139.
PorroCCianciulliAPanaroMA. The regulatory role of IL-10 in neurodegenerative diseases. Biomolecules2020; 10: 1017.
140.
KiyotaTIngrahamKLSwanRJ, et al.AAV serotype 2/1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP + PS1 mice. Gene Ther2012; 19: 724–733.
Sharifi-RadMAnil KumarNVZuccaP, et al.Lifestyle, oxidative stress, and antioxidants: Back and forth in the pathophysiology of chronic diseases. Front Physiol2020; 11: 694.
143.
HalliwellBGutteridgeJMC. Free radicals in biology and medicine. Oxford University Press, 2015.
144.
MartinsRNVillemagneVSohrabiHR, et al.Alzheimer’s disease: A journey from amyloid peptides and oxidative stress, to biomarker technologies and disease prevention strategies—gains from AIBL and DIAN cohort studies. J Alzheimers Dis2018; 62: 965–992.
145.
HensleyKHallNSubramaniamR, et al.Brain regional correspondence between Alzheimer’s disease histopathology and biomarkers of protein oxidation. J Neurochem1995; 65: 2146–2156.
146.
MandalMSarkarMKhanA, et al.Reactive oxygen species (ROS) and reactive nitrogen species (RNS) in plants– maintenance of structural individuality and functional blend. Adv Redox Res2022; 5: 100039.
147.
IovaO-MMarinG-ELazarI, et al.Nitric oxide/nitric oxide synthase system in the pathogenesis of neurodegenerative disorders—an overview. Antioxidants (Basel)2023; 12: 753.
148.
Di MeoSReedTTVendittiP, et al.Role of ROS and RNS sources in physiological and pathological conditions. Oxid Med Cell Longev2016; 2016: 1245049.
149.
OlufunmilayoEOGerke-DuncanMBHolsingerRMD. Oxidative stress and antioxidants in neurodegenerative disorders. Antioxidants2023; 12: 517.
JurcăuMCAndronie-CioaraFLJurcăuA, et al.The link between oxidative stress, mitochondrial dysfunction and neuroinflammation in the pathophysiology of Alzheimer’s disease: therapeutic implications and future perspectives. Antioxidants (Basel)2022; 11: 2167.
152.
XuYJinM-ZYangZ-Y, et al.Microglia in neurodegenerative diseases. Neural Regen Res2020; 16: 270–280.
153.
MhatreMFloydRAHensleyK. Oxidative stress and neuroinflammation in Alzheimer’s disease and amyotrophic lateral sclerosis: common links and potential therapeutic targets. J Alzheimers Dis2004; 6: 147–157.
154.
CorreiaASCardosoAValeN. Oxidative stress in depression: the link with the stress response, neuroinflammation, serotonin, neurogenesis and synaptic plasticity. Antioxidants2023; 12: 470.
155.
BishtKSharmaKTremblayM-È. Chronic stress as a risk factor for Alzheimer’s disease: Roles of microglia-mediated synaptic remodeling, inflammation, and oxidative stress. Neurobiol Stress2018; 9: 9–21.
156.
CarusoGCaraciFJolivetRB. Pivotal role of carnosine in the modulation of brain cells activity: Multimodal mechanism of action and therapeutic potential in neurodegenerative disorders. Prog Neurobiol2019; 175: 35–53.
157.
HuangXAtwoodCSHartshornMA, et al.The A beta peptide of Alzheimer’s disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry1999; 38: 7609–7616.
158.
RobinsonKAStewartCAPyeQN, et al.Redox-sensitive protein phosphatase activity regulates the phosphorylation state of p38 protein kinase in primary astrocyte culture. J Neurosci Res1999; 55: 724–732.
159.
HensleyKMaidtMLYuZ, et al.Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci1998; 18: 8126–8132.
160.
HaasJStorch-HagenlocherBBiessmannA, et al.Inducible nitric oxide synthase and argininosuccinate synthetase: co-induction in brain tissue of patients with Alzheimer’s dementia and following stimulation with beta-amyloid 1-42 in vitro. Neurosci Lett2002; 322: 121–125.
161.
ElgenaidiISSpiersJP. Regulation of the phosphoprotein phosphatase 2A system and its modulation during oxidative stress: A potential therapeutic target?Pharmacol Ther2019; 198: 68–89.
162.
Toral-RiosDPichardo-RojasPSAlonso-VanegasM, et al.GSK3β and tau protein in Alzheimer’s disease and epilepsy. Front Cell Neurosci2020; 14: 19.
163.
PerluigiMDi DomenicoFBaroneE, et al.mTOR in Alzheimer disease and its earlier stages: links to oxidative damage in the progression of this dementing disorder. Free Radic Biol Med2021; 169: 382–396.
164.
MedaLBernasconiSBonaiutoC, et al.Beta-amyloid (25-35) peptide and IFN-gamma synergistically induce the production of the chemotactic cytokine MCP-1/JE in monocytes and microglial cells. J Immunol1996; 157: 1213–1218.
165.
YamamotoKArakawaTUedaN, et al.Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem1995; 270: 31315–31320.
166.
WooCHEomYWYooMH, et al.Tumor necrosis factor-alpha generates reactive oxygen species via a cytosolic phospholipase A2-linked cascade. J Biol Chem2000; 275: 32357–32362.
167.
ChitnisTWeinerHL. CNS inflammation and neurodegeneration. J Clin Invest127: 3577–3587.
168.
VezzaniBCarinciMPatergnaniS, et al.The dichotomous role of inflammation in the CNS: A mitochondrial point of view. Biomolecules2020; 10: 1437.
169.
BehlTMakkarRSehgalA, et al.Current trends in neurodegeneration: Cross talks between oxidative stress, cell death, and inflammation. Int J Mol Sci2021; 22: 7432.
170.
ShaftelSSGriffinWSTO’BanionMK. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation2008; 5: 7.
171.
MartinonFBurnsKTschoppJ. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell2002; 10: 417–426.
172.
LamkanfiMDixitVM. Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol2012; 28: 137–161.
173.
BrozPDixitVM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol2016; 16: 407–420.
174.
MakoniNJNicholsMR. The intricate biophysical puzzle of caspase-1 activation. Arch Biochem Biophys2021; 699: 108753.
175.
LamkanfiMDixitVM. Mechanisms and functions of inflammasomes. Cell2014; 157: 1013–1022.
176.
BoraschiDItalianiPMiglioriniP, et al.Cause or consequence? The role of IL-1 family cytokines and receptors in neuroinflammatory and neurodegenerative diseases. Front Immunol2023; 14: 1128190.
177.
AllanSMTyrrellPJRothwellNJ. Interleukin-1 and neuronal injury. Nat Rev Immunol2005; 5: 629–640.
178.
AlboniSCerviaDSugamaS, et al.Interleukin 18 in the CNS. J Neuroinflammation2010; 7: 9.
HenekaMTMcManusRMLatzE. Inflammasome signalling in brain function and neurodegenerative disease. Nat Rev Neurosci2018; 19: 610–621.
181.
TsaiS-J. Effects of interleukin-1beta polymorphisms on brain function and behavior in healthy and psychiatric disease conditions. Cytokine Growth Factor Rev2017; 37: 89–97.
182.
BelkhelfaMBederNMouhoubD, et al.The involvement of neuroinflammation and necroptosis in the hippocampus during vascular dementia. J Neuroimmunol2018; 320: 48–57.
183.
ZhangSTangMLuoH, et al.Necroptosis in neurodegenerative diseases: a potential therapeutic target. Cell Death Dis2017; 8: e2905.
184.
YuanJAminPOfengeimD. Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases. Nat Rev Neurosci2019; 20: 19–33.
185.
DuboisHSorgeloosFSarvestaniST, et al.Nlrp3 inflammasome activation and Gasdermin D-driven pyroptosis are immunopathogenic upon gastrointestinal norovirus infection. PLoS Pathog2019; 15: e1007709.
186.
KaushalVDyeRPakavathkumarP, et al.Neuronal NLRP1 inflammasome activation of Caspase-1 coordinately regulates inflammatory interleukin-1-beta production and axonal degeneration-associated Caspase-6 activation. Cell Death Differ2015; 22: 1676–1686.
187.
FreemanLGuoHDavidCN, et al.NLR members NLRC4 and NLRP3 mediate sterile inflammasome activation in microglia and astrocytes. J Exp Med2017; 214: 1351–1370.
188.
SimardARSouletDGowingG, et al.Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer’s disease. Neuron2006; 49: 489–502.
189.
GriffinWSStanleyLCLingC, et al.Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A1989; 86: 7611–7615.
190.
MoonenSKoperMJVan SchoorE, et al.Pyroptosis in Alzheimer’s disease: cell type-specific activation in microglia, astrocytes and neurons. Acta Neuropathol2023; 145: 175–195.
191.
BaiHZhangQ. Activation of NLRP3 inflammasome and onset of Alzheimer’s disease. Front Immunol2021; 12: 701282.
192.
McGeerPLRogersJMcGeerEG. Inflammation, antiinflammatory agents, and Alzheimer’s disease: The last 22 years. J Alzheimers Dis2016; 54: 853–857.
193.
YangQ-QZhouJ-W. Neuroinflammation in the central nervous system: Symphony of glial cells. Glia2019; 67: 1017–1035.
194.
HanslikKLUllandTK. The role of microglia and the Nlrp3 inflammasome in Alzheimer’s disease. Front Neurol2020; 11: 570711.
195.
LiYHuangHLiuB, et al.Inflammasomes as therapeutic targets in human diseases. Signal Transduct Target Ther2021; 6: 247.
196.
AhmedMEIyerSThangavelR, et al.Co-localization of glia maturation factor with NLRP3 inflammasome and autophagosome markers in human Alzheimer’s disease brain. J Alzheimers Dis2017; 60: 1143–1160.
197.
SaresellaMLa RosaFPianconeF, et al.The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer’s disease. Mol Neurodegener2016; 11: 23.
198.
DempseyCRubio AraizABrysonKJ, et al.Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-β and cognitive function in APP/PS1 mice. Brain Behav Immun2017; 61: 306–316.
199.
TschoppJSchroderK. NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production?Nat Rev Immunol2010; 10: 210–215.
200.
ZhouRYazdiASMenuP, et al.A role for mitochondria in NLRP3 inflammasome activation. Nature2011; 469: 221–225.
201.
LiuLChanC. IPAF inflammasome is involved in IL-1β production from astrocytes, induced by palmitate; implications for Alzheimer’s disease. Neurobiol Aging2014; 35: 309–321.
202.
HalleAHornungVPetzoldGC, et al.The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nat Immunol2008; 9: 857–865.
203.
CraftJMWattersonDMHirschE, et al.Interleukin 1 receptor antagonist knockout mice show enhanced microglial activation and neuronal damage induced by intracerebroventricular infusion of human β-amyloid. J Neuroinflammation2005; 2: 15.
204.
ShengJGItoKSkinnerRD, et al.In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging1996; 17: 761–766.
205.
ShaftelSSKyrkanidesSOlschowkaJA, et al.Sustained hippocampal IL-1β overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest2007; 117: 1595–1604.
206.
KambohMIDemirciFYWangX, et al.Genome-wide association study of Alzheimer’s disease. Transl Psychiatry2012; 2: e117.
207.
HollingworthPHaroldDSimsR, et al.Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet2011; 43: 429–435.
208.
ZhangBGaiteriCBodeaL-G, et al.Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer’s disease. Cell2013; 153: 707–720.
209.
PontilloACatamoEArosioB, et al.NALP1/NLRP1 genetic variants are associated with Alzheimer disease. Alzheimer Dis Assoc Disord2012; 26: 277–281.
210.
TanMSTanLJiangT, et al.Amyloid-β induces NLRP1-dependent neuronal pyroptosis in models of Alzheimer’s disease. Cell Death Dis2014; 5: e1382.
211.
SivananthanSNLeeAWGoodyerCG, et al.Familial amyloid precursor protein mutants cause caspase-6-dependent but amyloid β-peptide-independent neuronal degeneration in primary human neuron cultures. Cell Death Dis2010; 1: e100.
212.
NikolaevAMcLaughlinTO’LearyD, et al.N-APP binds DR6 to cause axon pruning and neuron death via distinct caspases. Nature2009; 457: 981–989.
213.
UribeVWongBKYGrahamRK, et al.Rescue from excitotoxicity and axonal degeneration accompanied by age-dependent behavioral and neuroanatomical alterations in caspase-6-deficient mice. Hum Mol Genet2012; 21: 1954.
214.
LeBlancALiuHGoodyerC, et al.Caspase-6 role in apoptosis of human neurons, amyloidogenesis, and Alzheimer’s disease. J Biol Chem1999; 274: 23426–23436.
215.
AdwanLSubaieaGMZawiaNH. Tolfenamic acid downregulates BACE1 and protects against lead-induced upregulation of Alzheimer’s disease related biomarkers. Neuropharmacology2014; 79: 596–602.
216.
SubaieaGMAdwanLIAhmedAH, et al.Short-term treatment with tolfenamic acid improves cognitive functions in AD mice. Neurobiol Aging2013; 34: 2421–2430.
217.
SubaieaGMAhmedAHAdwanLI, et al.Reduction of amyloid-β deposition and attenuation of memory deficits by tolfenamic acid. J Alzheimers Dis2015; 43: 425–433.
218.
CouturierJStancuI-CSchakmanO, et al.Activation of phagocytic activity in astrocytes by reduced expression of the inflammasome component ASC and its implication in a mouse model of Alzheimer disease. J Neuroinflammation2016; 13: 20.
219.
MaYJiangJGaoY, et al.Research progress of the relationship between pyroptosis and disease. Am J Transl Res2018; 10: 2213–2219.
220.
McKenzieBADixitVMPowerC. Fiery cell death: Pyroptosis in the central nervous system. Trends Neurosci2020; 43: 55–73.
221.
ShiJZhaoYWangK, et al.Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature2015; 526: 660–665.
222.
BergsbakenTFinkSLCooksonBT. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol2009; 7: 99–109.
223.
RatherMAKhanAAlshahraniS, et al.Inflammation and Alzheimer's disease: mechanisms and therapeutic implications by natural products. Mediators Inflamm2021; 2021: 9982954.
224.
ChenYYuY. Tau and neuroinflammation in Alzheimer's disease: interplay mechanisms and clinical translation. J Neuroinflammation2023; 20: 165.
225.
ZelleraMVDiasaDSebastiaoAM, et al.NLRP3 Inflammasome: a starring role in amyloid-and tau-driven pathological events in Alzheimer’s disease. J Alzheimers Dis2021; 83: 939–961.
